Acute renal failure after treatment with sunitinib in a patient with multiple myeloma

Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Nelson, Saucier, Nathan A., Zeldenrust, Steven R., Gunderson, Heidi D., Cornell, Lynn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421250/
https://www.ncbi.nlm.nih.gov/pubmed/25984018
http://dx.doi.org/10.1093/ndtplus/sfp037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421250/
https://www.ncbi.nlm.nih.gov/pubmed/25984018
http://dx.doi.org/10.1093/ndtplus/sfp037

Ejemplares similares